Management of Elevated Microalbumin Ratio in Patients on Losartan

Current Evidence Supporting Losartan Continuation

The American Diabetes Association recommends that for patients with diabetes and elevated urinary albumin-to-creatinine ratio (UACR), either an ACE inhibitor or ARB like losartan is strongly recommended, with Grade B evidence for UACR 30-299 mg/g and Grade A evidence for UACR ≥300 mg/g 1, 2, 3, 4
For UACR 30-299 mg/g (moderately elevated albuminuria), ACE inhibitor or ARB is recommended, with Grade B evidence 1, 2, 4
For UACR ≥300 mg/g (severely elevated albuminuria), ACE inhibitor or ARB is strongly recommended, with Grade A evidence 1, 2, 3, 4

The American College of Cardiology recommends titrating losartan from 50 mg to 100 mg daily if not already at maximum dose, as the antiproteinuric effect is dose-dependent, although the specific evidence is not provided in the non-ignored references

The National Kidney Foundation recommends checking serum creatinine and potassium within 1-2 weeks after initiating or increasing losartan dose, with specific guidelines for acceptable vs. concerning creatinine changes 1, 2, 3, 4, 5
A 10-20% increase in creatinine is expected and considered a hemodynamic effect, while a >20% but <30% increase may require dose reduction, and a >30% increase within 4 weeks requires discontinuation of losartan 5
Baseline potassium must be <5.0 mmol/L before initiation, and monitoring for hyperkalemia is essential, especially if eGFR <60 mL/min/1.73 m² 1, 2, 4, 5

The American Diabetes Association recommends optimizing glycemic control aggressively, with a Grade A recommendation, to reduce the risk and slow the progression of diabetic kidney disease independent of RAAS blockade 1, 2, 3, 4
The American Heart Association recommends optimizing blood pressure control, with a Grade A recommendation, to reduce the risk or slow the progression of diabetic kidney disease, targeting BP <130/80 mmHg in patients with diabetes and CKD 1, 2, 3, 4, 7, 8
Consider adding an SGLT2 inhibitor if eGFR ≥30 mL/min/1.73 m² and UACR >300 mg/g, with a Grade A recommendation, to provide additional cardiovascular and renal protection beyond RAAS blockade 2, 4

The National Kidney Foundation recommends reassessing UACR at least annually to monitor treatment response and disease progression, with continued monitoring of UACR in patients with albuminuria on ACE inhibitor or ARB to assess response 1, 2, 3, 8
Annual eGFR assessment is mandatory, with evaluation and management of complications of CKD when eGFR <60 mL/min/1.73 m², and consideration of nephrology referral when eGFR <30 mL/min/1.73 m² or for uncertain etiology 1, 2, 3, 4

The American Kidney Foundation recommends never combining losartan with an ACE inhibitor, as this increases risks of hyperkalemia and acute kidney injury without improving outcomes 8, 9, 5
Temporarily suspending losartan during intercurrent illness with volume depletion, planned IV radiocontrast administration, bowel preparation for colonoscopy, or prior to major surgery is recommended 5, 6